BioSpace News Archive

To better address the current challenges with the nation’s blood supply, AABB (Association for the Advancement of Blood & Biotherapies) is launching the Alliance for a Strong Blood Supply.

Genesis MedTech Group has completed the acquisition of JC Medical, a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases.

Endovascular procedures have gained increased traction in clinical practice, especially in acute ischemic strokes and for a wide range of aneurysm repair.

Blood clot retrieval devices are also known as thrombectomy devices. Thrombectomy is an interventional procedure, performed primarily on coronary arteries, peripheral arteries, and cerebral arteries.

The World Health Organization states that there will be 22 million new cases of cancer in the next two decades, which is a staggering figure.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.

Elekta invites analysts and investors to a presentation of the third quarter 2021/22 at 10:00 a.m. CET on February 24.

Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share.

Immunovia will publish its full year 2021 results on 17 February 2022 at 08:30 am CET.

Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV.